AKBA
Akebia Therapeutics Inc.
-38.05%
$1.13 - $0.70
Feb 7th 2023 - Mar 21st 2023
Feb, 23, 2023
Anemia associated with chronic kidney disease is a... See more
Jan, 7, 2023
May you all never be short on love, happiness, and health! 🍻
Feb, 23, 2023
Anemia associated with chronic kidney disease is a significant global health issue, and vadadustat is a highly effective treatment option that could lead to significant revenue growth for Akebia.
Jan, 7, 2023
May you all never be short on love, happiness, and health! 🍻
Dec, 8, 2022
$AKBA .35 break coming.. $spy $qqq $xbi $LABU .. good revenue.. eu opinion and approval soon.. partnership soon.. fda resubmit news.. ards with ut health news possible .
Nov, 22, 2022
Health wealth and family.
Nov, 3, 2022
The ARDS study also is looking promising especially on what Butler said about using broad ARDS population that is older n sicker where u can see better vad drug separation vs younger patients for Covid ARDS that UT health ran.